Biohit test receives further proof of its effectiveness in the UK

Translation: Original published in Finnish on 1/9/2025 at 7:09 am EET.

Biohit announced on Wednesday the results of a study of GastroPanel® for the diagnosis of gastric precancerous conditions. The GastroPanel® test on a blood sample identified patients at risk of gastric cancer requiring further examinations with over 90% accuracy. The results are consistent with previous similar studies. The study may support broader commercialization of the GastroPanel® test in the UK, where the company operates through its subsidiary. We anticipate rapid growth for Biohit in the coming years. This news further supports that growth outlook.

Biohit builds the foundation for the use of GastroPanel® in the British National Health Service

The study now reported was conducted at Homerton University Hospital in London. The clinical study investigated the accuracy of the GastroPanel® test in identifying the risk conditions of gastric cancer in patients with upper abdominal complaints. The test, which is performed on a blood sample, disclosed the patients at a high risk of gastric cancer and requiring further examinations from those with a healthy stomach with >90% accuracy. We understand that similar studies have been done in the world before and the results are in line with the results published here. However, this study was the first of its kind in the UK and may contribute to the introduction of GastroPanel® in the British National Health Service (NHS). Biohit already sells GastroPanel® tests in the UK through its subsidiary and sees further growth opportunities in the NHS. According to Biohit, the use of the test could reduce the need for expensive and painful gastrointestinal endoscopic examinations, which also have limited capacity.

Fast growth expected in the coming years

Biohit is targeting strong annual growth of 15-20% over the strategy period 2024-2028. Our forecasts also predict strong growth. The news of efforts to expand the market is therefore in line with our expectations and does not give rise to any forecast changes at this stage. Biohit will publish its financial statements on February 12, which will provide more detailed information on the company's development.